Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19 TORONTO, Canada -- April 18, 2022 -- InvestorsHub NewsWire -- Revive...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 TORONTO, Canada -- April 12, 2022 -- InvestorsHub NewsWire -- Revive...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Expected to seek DSMB approval to proceed with EUA application to the FDA in...
HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive...
Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation TORONTO, February 15, 2022 -- Revive...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19Ethics Committee approval to proceed with Phase 3 clinical trial in Turkey13 clinical sites selected to...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 701 subjects dosed to date Initiating enrollment activities in Turkey as part of its...
Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film...
Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19 Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment...
Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant TORONTO, November 16, 2021 -- InvestorsHub NewsWire -- Revive...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.001 | 19.6078431373 | 0.0051 | 0.0065 | 0.0051 | 108770 | 0.0059964 | CS |
| 4 | 0 | 0 | 0.0061 | 0.0067 | 0.005 | 394669 | 0.00600529 | CS |
| 12 | -0.0005 | -7.57575757576 | 0.0066 | 0.012 | 0.005 | 457670 | 0.00700232 | CS |
| 26 | -0.0043 | -41.3461538462 | 0.0104 | 0.0135 | 0.005 | 382173 | 0.00724582 | CS |
| 52 | -0.0185 | -75.2032520325 | 0.0246 | 0.036 | 0.005 | 350144 | 0.01263091 | CS |
| 156 | -0.2345 | -97.4646716542 | 0.2406 | 0.39 | 0.005 | 433488 | 0.10422604 | CS |
| 260 | -0.029454 | -82.8429993812 | 0.035554 | 0.72 | 0.005 | 1065320 | 0.27579268 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
